Grants and Contributions:
Title:
Preclinical Development of Novel Therapeutics for Rare Brain Disease
Agreement Number:
919085
Agreement Value:
$302,000.00
Agreement Date:
Jan 2, 2019 - Mar 15, 2020
Description:
Novel small molecule modulators as potential therapeutics for a rare brain disease, Niemann-Pick Type C, will be evaluated in preclinical studies.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burnaby, British Columbia, CA V5A 4B5
Reference Number:
172-2018-2019-Q4-919085
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
851456152
Recipient Type:
For-profit organization
Recipient's Legal Name:
Alectos Therapeutics Inc.
Federal Riding Name:
Burnaby North--Seymour
Federal Riding Number:
59002
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710